Detalhe da pesquisa
1.
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Br J Haematol
; 204(6): 2227-2232, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38504552
2.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 99(7): 1257-1268, 2024 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-38622840
3.
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Br J Haematol
; 199(3): 355-365, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36111391
4.
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Oncologist
; 27(7): e589-e596, 2022 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35462406
5.
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Future Oncol
; 18(40): 4443-4456, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36799429
6.
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Am J Hematol
; 92(5): 420-428, 2017 May.
Artigo
Inglês
| MEDLINE | ID: mdl-28142202
7.
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Blood Cancer J
; 14(1): 69, 2024 Apr 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38649340
8.
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Transplant Cell Ther
; 29(3): 174.e1-174.e10, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36494017
9.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Lancet Haematol
; 10(10): e825-e837, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37708911
10.
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
Blood Cancer J
; 12(4): 63, 2022 04 13.
Artigo
Inglês
| MEDLINE | ID: mdl-35418120